Successful prevention of severe allergic transfusion reactions with omalizumab.

CONCLUSION: This case suggests that omalizumab is a promising new alternative treatment for the prevention of severe ATRs. PMID: 32134497 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32134497?dopt=Abstract

Source: Transfusion - March 4, 2020 Category: Hematology Authors: Shi S, Han J, Yao Y, Xu Y, Wu D, Wang Y Tags: Transfusion Source Type: research